A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma

American Journal of Hematology

Volumn 90, Issue 1, 2015, Pages 42-49

  Orlowski, Robert Z ^a   Gercheva, Liana ^b   Williams, Cathy ^c   Sutherland, Heather ^d   Robak, Tadeusz ^e   Masszi, Tamás ^f   Goranova Marinova, Vesselina ^g   Dimopoulos, Meletios A ^h   Cavenagh, James D ⁱ   Špička, Ivan ^j   Maiolino, Angelo ^k   Suvorov, Alexander ^l   Bladé, Joan ^m   Samoylova, Olga ⁿ   Puchalski, Thomas A ^o   Reddy, Manjula ^o   Bandekar, Rajesh ^o   van de Velde, Helgi ^o   Xie, Hong ^o   Rossi, Jean Franois ^p  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY HOSPITAL ST MARINA   (Bulgaria)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f Szent Laszlo Hospital   (Hungary)

^g Division of Nephrology and Hemodialysis   (Bulgaria)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^j CHARLES UNIVERSITY   (Czech Republic)

^k FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^l First Republican Clinical Hospital of Udmurtia   (Russian Federation)

^m INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁿ LOBACHEVSKY STATE UNIVERSITY OF NIZHNY NOVGOROD   (Russian Federation)

^o JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^p HÔPITAL SAINT ELOI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BORTEZOMIB; C REACTIVE PROTEIN; COLONY STIMULATING FACTOR; DEXAMETHASONE; HEMOGLOBIN; INTERLEUKIN 6; LENALIDOMIDE; PLACEBO; SILTUXIMAB; TRIACYLGLYCEROL; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IL6 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BLOOD TRANSFUSION; BRONCHITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEURALGIA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SALVAGE THERAPY; SENSORY NEUROPATHY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; RECURRENT DISEASE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE;

EID: 84919683208     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23868     Document Type: Article

References (32)

1. Rawstron AC, Fenton JA, Ashcroft J, et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000;96:3880-3886.
2. Pelliniemi TT, Irjala K, Mattila K, et al. Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Finnish Leukemia Group. Blood 1995;85:765-771.
3. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29:3945-3950.
4. Jourdan M, Veyrune JL, De Vos J, et al. A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells. Oncogene 2003;22:2950-2959.
5. Holub MC, Hegyesi H, Igaz P, et al. Soluble interleukin-6 receptor enhanced by oncostatin M induces major changes in gene expression profile of human hepatoma cells. Immunol Lett 2002;82:79-84.
6. Dankbar B, Padró T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000;95:2630-2636.
7. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001;15:1950-1961.
8. Le Gouill S, Podar K, Amiot M, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood 2004;104:2886-2892.
9. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498.
10. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-917.
11. Voorhees PM, Chen Q, Kuhn DJ, et al. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma. Clin Cancer Res 2007;13:6469-6478.
12. Voorhees PM, Chen Q, Small GW, et al. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death. Br J Haematol 2009;145:481-490.
13. Ogata A, Chauhan D, Teoh G, et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997;159:2212-2221.
14. Stephanou A, Isenberg DA, Nakajima K, Latchman DS. Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem 1999;274:1723-1728.
15. Kurzrock R, Voorhees PM, Casper C, et al. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 2013;19:3659-3670.
16. Greipp PR, San Miguel J, Durie BG, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-3420.
17. Blade J, Samson D, Reece D, et al., for the Myeloma Subcommittee of the European Group for Blood and Marrow Transplant Chronic Leukaemia Working Party and the Myeloma Working Committee of the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-1123.
18. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-376.
19. Cella D, Lai JS, Chang CH, et al. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 2002;94:528-538.
20. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 1994;23:129-138.
21. Puchalski T, Prabhakar U, Jiao Q, et al. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010;16:1652-1661.
22. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
23. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol 2011;12:431-440.
24. Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003;22:8386-8393.
25. Xie L, Li LY, Kurzrock R, et al. Population pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody, siltuximab (CNTO 328), in patients with B-cell non-Hodgkin's lymphoma, multiple myeloma, or Castleman's disease. Blood 2012;120:Abstract 1365.
26. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009;9:665-674.
27. Frassanito MA, Cusmai A, Iodice G, Dammacco F. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. Blood 2001;97:483-489.
28. Alberti L, Thomachot MC, Bachelot T, et al. IL-6 as an intracrine growth factor for renal carcinoma cell lines. Int J Cancer 2004;111:653-661.
29. Mahtouk K, Moreaux J, Hose D, et al. Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays. BMC Cancer 2010;10:198.
30. Voorhees PM, Manges RF, Sonneveld P, et al. A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;161:357-366.
31. San Miguel J, Bladé J, Shpilberg O, et al. Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma. Blood 2014;123:4136-4142.
32. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003;9:4653-4665.